Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The vaginal epithelial surface and local microbial community constitute a complex biological system that functions as a critical protective barrier in the female reproductive tract. The non-keratinized stratified squamous epithelium provides structural integrity and immune sensing, while the symbiotic microbiota—primarily Lactobacillus species—maintains a low pH (3.5–4.5) through the fermentation of glycogen-derived products into lactic acid (Ravel et al., 2011). This acidic environment, along with the production of antimicrobial peptides and hydrogen peroxide, inhibits the colonization of pathogenic organisms and maintains local immune homeostasis (O'Hanlon et al., 2013). Disruptions to this ecosystem, known as dysbiosis, are associated with increased risks of bacterial vaginosis, yeast infections, and the acquisition of sexually transmitted infections, including HIV (Coudray & Madhivanan, 2020). Therapeutic strategies targeting this environment include the use of localized antimicrobials to treat infections, probiotics to restore healthy flora, and microbicides designed to prevent pathogen transmission at the mucosal interface (Hickey et al., 2011). Because this entity represents a multi-component ecological niche involving host-microbe interactions rather than a single protein or gene, it is categorized as a biological system or microbiome rather than a discrete molecular therapeutic target.
Therapeutic interventions targeting this system function by eliminating pathogenic overgrowth through antimicrobial action, restoring the protective acidic environment via lactic acid production or supplementation, promoting the colonization of beneficial commensal bacteria like Lactobacillus to achieve competitive exclusion, and enhancing the physical and immunological barrier properties of the vaginal epithelium to prevent pathogen entry and transmission (Workowski et al., 2021; Hickey et al., 2011; O'Hanlon et al., 2013).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaginal epithelial surface and local microbial community.